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Circulating antinuclear autoantibodies (ANA) are useful as diagnostic markers for a variety of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren syndrome (reviewed by Tan, 1989) . 1 The presence of ANA is usually tested by immunofluorescence using human HEp-2 cells. However, the use of this cell line does not detect the presence of all ANA, an observation which has given rise to the concept of "ANA negative lupus." The autoantigen that is most commonly not detected in these cases of "ANA negative lupus" is the Ro/SS-A antigen, which belongs to the group of extractable nuclear antigens (ENA).
Antibodies to Ro/SS-A were first identified by gel diVusion in patients with Sjögren syndrome in 1962 2 and in patients with SLE in 1969. 3 These autoantibodies are almost invariably associated with subacute cutaneous lupus erythematosus and neonatal lupus erythematosus and may be the only antibody present in patients with SLE or Sjögren syndrome (reviewed by Reichlin and Scofield, 1996 4 ). Ro/SS-A together with La/SS-B is associated with hY (human cytoplasmic) uridine-rich RNA. These antibodies recognise two proteins of 60 kDa and 52 kDa, of which the 60 kDa protein is the major polypeptide. 5 Most if not all 60 kDa Ro/SS-A antibodies react with conformational epitopes on the native protein, demonstrable by immunodiVusion or by counterimmunoelectrophesis (CIEP), and are not detectable by immunoblotting. 6 In contrast, antibodies to 52 kDa Ro/SS-A protein preferentially react with denatured epitopes by immunoblotting. 6 The most sensitive methods for the detection of Ro/SS-A are by a sandwich ELISA and by immunoprecipitation. 7 However, the enhanced sensitivity of the latter two methods detects the presence of small amounts of antibody in asymptomatic patients, 8 therefore decreasing the diagnostic significance of the assays. Because of these considerations, the current preferred screening assay for Ro/SS-A is the less sensitive gel diVusion assay. This is less than ideal, given that the screening assay for ANA is the immunofluorescence test.
To overcome the problem of the detection of Ro/SS-A by immunofluorescence, HEp-2 cells have been transfected with human 60 kDa Ro/SS-A protein. [9] [10] [11] As only about 10-15% of transfected HEp2 cells overexpress the 60 kDa Ro/SS-A protein, the cell line can also be used for screening for other ANA specificities. Initial reports using this 60 kDa Ro-transfected HEp-2 cell line have been promising. Here we report our experience using this cell line for screening 10 500 serum samples for Ro/SS-A antibodies by immunofluorescence in a routine diagnostic laboratory. Our report is the largest survey for anti Ro/SS-A antibodies by immunofluorescence to date.
Methods

SERA
Sera from 10 500 patients were referred for routine tests for antinuclear antibody, predominantly from general practitioners but about 20% from specialists. These included sera from 946 patients referred for testing for antibodies to extractable nuclear antigens.
IMMUNOFLUORESCENCE
Sera were screened at a dilution of 1:200 in phosphate buVered saline containing a serum diluent provided by the manufacturers to reduce the background immunofluorescence. The slides were screened using a Leitz immunofluorescence microscope and a ×50 objective to enhance the sensitivity of the detection of positive tests. We selected a screening dilution of 1:200 because preliminary studies carried out to determine the normal reference range in our laboratory had established that this screening dilution gave optimal discrimination between patients with systemic autoimmune diseases and age and sex matched healthy controls. The slides were read under ultraviolet light using ×500 magnification. ANA patterns and titres were determined on the "background" nonhyperexpressing cells, while the Ro/SS-A pattern was identified on the hyperexpressing cells. For photomicrography, the stained cells were examined by confocal microscopy (Bio-Rad MRC 1024).
IMMUNODIFFUSION
Sera for routine testing for ENA antibodies were screened by immunodiVusion using a commercial kit (Auto ID®, Immuno Concepts) according to the manufacturer's instructions. Sera were tested neat and wells were routinely double filled. Results were read at 48 hours.
ELISA
Any sera giving a precipitin line on immunodiVusion or any sera showing the Ro/SS-A pattern by immunofluorescence were further characterised by ELISA using a commercially available ELISA kit (RELISA® ENA, Immuno Concepts). These kits comprise an eight well strip coated with aYnity purified Sm, Sm/RNP, Ro/SS-A, La/SS-B, Scl70, and Jo-1. Sera positive by immunodiVusion but negative by ELISA were recorded as having unidentified precipitin lines (UPL). A result of > 40 units was considered positive. The manufacturers state that the ELISA kit has been compared with other similar ELISA assays as well as with other methods of detection including immunodiVusion, counterimmunoelectrophoresis, and immunoblotting. These comparisons showed that the ELISA kit gave a relative sensitivity, specificity, and overall agreement of 94-100%.
COUNTERIMMUNOELECTROPHORESIS
This test was carried out as described previously. 
Results
ROUTINE IMMUNOFLUORESCENCE SCREENING FOR RO/SS-A ANTIBODIES
Antinuclear antibodies were detected in 2100 serum samples from 10 500 sera sent to Gribble's Pathology (Melbourne branch) for tests for ANA, giving a positive detection rate of 20%. Cells hyperexpressing Ro/SS-A (Ro/SS-A pattern) were detected by immunofluorescence in 160 serum samples, comprising 8% (160/ 2100) of all the positive ANA identified. The Ro/SS-A pattern seen in 10-15% of transfected cells typically comprised prominent staining of nucleoli combined with diVuse staining of the nucleoplasm as previously described 9 10 ( fig 1A) . Occasionally, hyperexpressing cells showed strong staining only of the nucleoplasm without staining of nucleoli ( fig 1B) , a pattern which has not previously been reported.
Fifty of the 160 sera which tested positive for Ro/SS-A by immunofluorescence using the Hep-2 transfected cells were previously shown to be positive for Ro/SS-A by immunodiffusion or by ELISA. Therefore only the remaining 110 newly diagnosed Ro/SS-A positive sera were subjected to further tests. Antibody titres were determined for these 110 sera. These titres were obtained by doubling serum dilutions screened on the 85-90% "background" non-hyperexpressing, transfected HEp-2 cells which did not show the Ro/SS-A pattern. These background non-hyperexpressing cells typically showed a speckled nucleus staining pattern with the exception of one serum showing a centromere pattern and three sera showing a homogeneous staining pattern. The results showed that of the 110 newly diagnosed Ro/SS-A positive sera, seven tested negative for ANA (titre < 200), 33 had ANA titres at 200, and 70 had titres > 200 (table 1). All 110 samples were also positive for Ro/SS-A antibodies by ELISA (table 2) .
Seven of 110 Ro/SS-A positive sera (6%) had ANA titres below our reference range (< 1:200) in the non-hyperexpressing, transfected HEp-2 cells. Subsequent testing at lower serum dilutions failed to show the presence of ANA in the "background" cells by immunofluorescence. Therefore these sera would have been reported as "ANA negative" using conventional HEp-2 cells.
TESTS FOR EXTRACTABLE NUCLEAR ANTIGENS
Over the same period, we also carried out tests for ENA on 946 sera in which these tests were requested, irrespective of whether or not Ro/SS-A antibodies had been demonstrated by immunofluorescence. We tested for ENA antibodies by immunodiVusion followed by ELISA (on sera giving precipitin lines). In all, 192 sera tested positive for ENA, including the 110 Ro/SS-A positive sera detected by immunofluorescence. An additional 15 Ro/SS-A positive sera were identified, giving a total of 125 Ro/SS-A positive sera identified by ELISA. The positive predictive value of the immunofluorescence test for Ro/SS-A using the transfected cell line was 100% (160/160) and the sensitivity was 91% (160/175). However, as not all sera sent for ANA testing were screened for Ro/SS-A antibodies by immunofluorescence, it is possible that the sensitivity of the test may be less than 91%. 
Discussion
HEp-2 cells transfected with the human 60 kDa Ro/SS-A protein were developed to overcome the insensitivity of the detection of Ro/SS-A antibodies by immunofluorescence using conventional HEp-2 cells. 9 The increased sensitivity for the detection of these antibodies is based on the overexpression of the 60 kDa Ro/SS-A protein in about 10-15% of cells. In a comparison of end point titres of 20 Ro/SS-A positive sera on transfected versus non-transfected HEp-2 cells, the overexpressing cells gave an increased mean titre which was 41-fold higher than that of the non-transfected cells. The concordance rate for the detection of Ro/SS-A antibodies in 39 of 53 patients with primary Sjögren syndrome using the 60 kDa Ro/SS-A transfected cell line and CIEP was 100%. 10 In another study, 69 of 73 sera (95%) which were positive for Ro/SS-A by immunodiVusion were also positive by immunofluorescence using the 60 kDa Ro/SS-A transfected cell line.
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In a previous study, 14 Ro/SS-A positive sera were detected from a total of 240 sera tested using the 60 kDa Ro/SS-A transfected cell line for routine ANA screening. 9 Here, we report the detection of 160 Ro/SS-A positive sera from 10 500 sera screened for ANA, representing therefore the largest experience with the use of this cell line for routine ANA screening to date. We used a screening serum dilution of 1:200, which is higher than the screening dilution of 1:40 used by other laboratories. It is possible that we may have missed the detection of some Ro/SSA positive sera by the use of this screening dilution. However, this is unlikely because cells transfected with human 60 kDa Ro/SSA dramatically overexpress this antigen, resulting in a 41-fold increase in titre compared with non-transfected cells. 9 The Ro/SS-A pattern was typically identified as hyperexpressing cells giving a combined immunofluorescence staining of both the nucleoplasm as well as the nucleolus, a pattern consistent with that of previous reports. [9] [10] [11] In the present study, we also describe one other immunofluorescence staining pattern which has not previously been reported-that is, strong immunofluorescence staining of the nucleoplasm only, without any staining of the nucleolus, in the hyperexpressing HEp-2 transfected cells. We have designated these two patterns of immunofluorescence staining in the hyperexpressing transfected HEp-2 cells as the "Ro/ SS-A pattern." All sera which gave the Ro/SS-A pattern by immunofluorescence were confirmed positive for this specificity by immunodiVusion or ELISA. The ANA status of the "background" non-hyperexpressing cells was negative in seven sera and weakly positive in 33. These observations highlight the value of using the transfected cell line. Importantly sera with negative or weakly positive ANA on the "background" cells had markedly increased ELISA units (> 100).
In a concurrent study of 192 sera which were tested for ENA by immunodiVusion followed by ELISA, 15 tested positive for Ro/SS-A in this way.These 15 sera did not give any immunofluorescence staining for the Ro/SS-A pattern in the HEp-2 cells transfected with the human 60 kDa Ro/SS-A protein. Given that the Ro/SS-A autoantigens comprise a 52 kDa as well as a 60 kDa protein, it is possible that antibody reactivity with the 52 kDa protein may have been missed in these 15 Ro/SS-A negative sera. However, in the present study, 14 of the 15 Ro/SS-A positive sera which tested negative for Ro/SS-A using the transfected cell line had ANA titres > 200, suggesting that the presence of these high titre antibodies may have masked the detection of Ro/SS-A antibodies.
CONCLUSIONS
Ro/SS-A antibodies comprise the majority of all ENA antibodies (65%) and are associated most commonly with SLE and Sjögren syndrome. With a positive predictive value of 100%, the HEp-2 cells transfected with human 60 kDa Ro/SS-A protein are a useful substrate for the routine detection of Ro/SS-A antibodies by immunofluorescence. Sera which test positive for Ro/SS-A antibodies by immunofluorescence should be subjected to further testing for other ENA antibodies by ELISA or by CIEP, because > 50% of sera may have other specificities in addition to Ro/SS-A, including La/ SS-B antibodies. Given a sensitivity detection rate in our hands of 91%, Ro/SS-A antibodies should be tested by other methods if screening for these antibodies using the transfected cell line is negative but clinical suspicion that they should be present is high. 
